Q1 2023 Cantargia AB Earnings Call Transcript
¶ -
It's a pleasure to present Cantargia's quarter one report. It's been a good start of the year for Cantargia. And during this period or directly after the period, we had a really good news flow. And we started out strongly by presenting new data in triple-negative breast cancer, which was part of the Phase I part of the early-in phase of a randomized trial called TRIFOUR, and we will have a quick look at those data later on. But what's noted is that directly afterwards, the first patient started treatment in randomized phase of trials and recruitment is now ongoing.
In our second program, CAN10, we also made some progress during the period, where GLP tox study was successfully completed and, later on, we could then send in the application to start the first clinical trial. And we will come back with timelines around that.
We also made a change to our Chief Financial Officer position, with Bengt Jöndell winding down and Patrik Renblad starting out. And what I'm going to say here is that we're just in the middle of the transition period
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
